Pemetinib tablets market price

Pemigatinib (Pemigatinib, trade name: Dabotan) is a targeted treatment for cholangiocarcinoma. It has demonstrated unique efficacy and potential in the field of anti-cancer. Pemetinib belongs to the class of kinase inhibitors, specifically potent inhibitors of the fibroblast growth factor receptor (FGFR). As a small molecule drug, pemetinib can easily penetrate cell membranes, penetrate deep into cells, and accurately interfere with the growth signals of tumor cells, thereby effectively inhibiting the proliferation and spread of tumor cells.

Pemetinib is unique in that it not only acts directly on tumor cells, but also further weakens the vitality of tumors by blocking the formation of new blood vessels required for tumor growth. This dual mechanism of action makes pemetinib excellent in treating certain types of tumors, such as cholangiocarcinoma and non-small cell lung cancer. Especially for those tumors with FGFR gene fusion or mutation, pemetinib has shown significant therapeutic effects.

The launch of pemetinib has brought new hope to many cancer patients who have failed traditional treatments. It changes the limitations of previous treatment options and provides patients with a more precise and effective treatment option. By inhibiting the growth signals of tumor cells, pemetinib can significantly extend patients' survival and improve their quality of life.

Of course, as a powerful targeted therapy drug, pemetinib also requires close cooperation between patients and doctors during its use, paying attention to possible side effects, such as eye discomfort, gastrointestinal reactions, etc., and adjusting the treatment plan in a timely manner. But overall, the emergence of pemetinib has undoubtedly brought new breakthroughs and progress in the field of anti-cancer treatment.

Pemetinib has been launched in the Chinese market and can be purchased directly by patients through domestic hospitals. Currently, the original version of pemetinib sold in China is 4.5 mg 14 tablets, and the market price is about 30,000 yuan. It is understood that both the original research version and the generic version exist in foreign markets. The original research version is priced at about 72,000 yuan in 13.5 mg and 14 tablets. The generic version produced by Lucius Pharmaceuticals in Laos is also in 4.5 mg x 14 tablets and costs only about 850 yuan. For more inquiries about pemetinib, patients are advised to contact regular overseas medical services.

xa0

Reference link: https://www.drugs.com/dosage/pemigatinib.html